IMpower150 shows positive benefit-risk profile with ABCP in nonsquamous NSCLC
29 Aug 2020
byDr Margaret Shi
The four-drug atezolizumab, bevacizumab, carboplatin and paclitaxel (ABCP) regimen is tolerable and manageable compared with the three-drug atezolizumab, carboplatin and paclitaxel (ACP) regimen and bevacizumab, carboplatin and paclitaxel (BCP) regimen for first-line treatment of nonsquamous non-small-cell lung cancer (NSCLC), according to safety and patient-reported outcome (PRO) data of the IMpower150 trial.